A First-in-Human Single and Multiple Ascending Dose Study of MT-701

Part of paid clinical trials in San Diego, California.

Sponsor
Mirador Therapeutics, Inc.
Study ID
NCT07396909
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • MT-701 — DRUG
    MT-701

Study Details

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.

Key Dates

Start date
Jan 12, 2026
Status verified
Feb 2026
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026

Study Design

Enrollment
46 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1- Single Ascending Dose
    To assess the safety and tolerability of single intravenous/subcutaneous dose of MT-701.
  • Experimental: Part 2- Multiple Ascending Dose
    To assess the safety and tolerability of multiple intravenous/subcutaneous doses of MT-701.

Primary Outcome Measure

Number of Subjects with non-SAEs and SAES [ Time Frame: Up to 14 days post dose ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mirador Clinical DepartmentSan DiegoCalifornia92121-

Find similar trials in San Diego, CA

By research site
Mirador Clinical Department· San Diego, CA

Related Studies